An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

Clinical Trial ID NCT01362296

Rank	Title	Journal	Year	PubWeight™‹?›
1	MEK and the inhibitors: from bench to bedside.	J Hematol Oncol	2013	1.90
2	Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.	Clin Cancer Res	2013	1.36
3	Targeted therapy for non-small-cell lung cancer: past, present and future.	Expert Rev Anticancer Ther	2013	1.22
4	The impact of genomic changes on treatment of lung cancer.	Am J Respir Crit Care Med	2013	1.18
5	A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.	Ann Oncol	2015	1.06
6	Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.	J Thorac Oncol	2015	0.97
7	Personalized medicine and treatment approaches in non-small-cell lung carcinoma.	Pharmgenomics Pers Med	2012	0.89
8	KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach.	Transl Lung Cancer Res	2013	0.84
9	Targeting MEK for the treatment of non-small-cell lung cancer.	J Thorac Oncol	2012	0.82
10	Recent advances in personalized lung cancer medicine.	Per Med	2014	0.82
11	Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials.	Curr Oncol	2012	0.81
12	Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma.	World J Clin Oncol	2013	0.79
13	Targeted therapy in cancer.	Cancer Chemother Pharmacol	2015	0.75
14	KRAS - An Evolving Cancer Target.	Austin J Cancer Clin Res	2016	0.75